文献速递胸部肿瘤放疗放疗物理与技术

贝叶斯学习优化局部晚期非小细胞肺癌放疗心脏剂量

Bayesian Learning to Reduce Cardiac Risk of Patients With Locally Advanced Non-Small Cell Lung Cancer Based on Personalized Radiation Therapy Prescription.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-12-07

该前瞻性研究采用贝叶斯连续学习与自适应框架,为局部晚期非小细胞肺癌患者制定个性化自适应放疗处方以降低心血管不良事件。研究纳入100例患者,前50例接受标准放疗,后50例接受个性化自适应放疗。个性化自适应放疗组高敏肌钙蛋白T升高发生率为20.5%,低于标准放疗组的31.9%。

要点

  • 个性化自适应放疗框架指导心脏剂量约束在临床可行。
  • 满足个性化自适应放疗剂量约束者hs-cTnT升高发生率仅9.7%。
  • 超出个性化自适应放疗剂量约束者hs-cTnT升高发生率达46.2%。

核心结论

  • 在前瞻性试验中实施个性化自适应放疗模型指导治疗决策是可行的。
  • 第一版个性化自适应放疗模型推荐的平均心脏剂量约束合理且具有临床相关性。
  • 个性化自适应放疗与较低的高敏肌钙蛋白T升高发生率相关。

研究设计与样本

  • 前瞻性研究,采用贝叶斯连续学习与自适应方法构建个性化自适应放疗框架。
  • 纳入局部晚期非小细胞肺癌患者,截至2025年7月31日共100例完成放疗。
  • 队列1(50例)接受标准放疗计划,队列2(50例)接受个性化自适应放疗。

主要发现

  • 队列1平均治疗平均心脏剂量为7.84 ± 6.30 Gy,队列2为6.36 ± 6.01 Gy(P = .20)。
  • 队列2高敏肌钙蛋白T升高发生率为20.5%,队列1为31.9%。
  • 队列2内满足个性化自适应放疗剂量约束者hs-cTnT升高发生率为9.7%,超出约束者为46.2%(P = .012)。

关键数值与推荐

  • 第一版模型纳入患者相关因素、疾病相关因素及平均心脏剂量作为风险因素。
  • 放疗后高敏肌钙蛋白T升高作为≥2级心血管不良事件的替代生物标志物用于实时决策。

临床怎么用

  • 可基于贝叶斯个性化风险预测模型指导局部晚期非小细胞肺癌患者的心脏剂量约束。
  • 利用放疗后hs-cTnT升高实时监测个性化自适应放疗效果并支持临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation-induced heart damage is a significant concern in the treatment of non-small cell lung cancer (NSCLC) that can have debilitating or life-threatening consequences. Current strategies focus on minimizing heart exposure, but individual susceptibility varies. Existing evidence also suggests that a uniform "one-size-fits-all" dosimetric constraint for the heart may not be optimal for all patients. METHODS AND MATERIALS: We developed a prospective study using Bayesian continuous learning and adaptation to develop a framework for personalized adaptive radiation treatment (PART) to reduce cardiovascular adverse events among patients with locally advanced NSCLC. The trial includes a Bayesian personalized risk prediction model to guide heart dose constraints; sequential learning to refine the model and the PART; continuous adaptation of the target risk level; and go/no-go monitoring of PART effectiveness in clinical implementation. Elevation of high-sensitivity cardiac troponin T (hs-cTnT) after radiation was used as a surrogate biomarker for grade ≥2 cardiovascular adverse events to allow real-time decision-making. RESULTS: As of July 31, 2025, 100 patients have been enrolled and completed radiation treatment. Standard radiation plans were implemented for cohort 1 (50 patients), and PART for cohort 2 (50 patients). The first model incorporated patient- and disease-related factors and mean heart dose (MHD) as risk factors. The average treated MHDs were 7.84 ± 6.30 Gy in cohort 1 and 6.36 ± 6.01 Gy in cohort 2 (P = .20). The incidence of hs-cTnT elevation was 20.5% in cohort 2 compared with 31.9% in cohort 1. Within cohort 2, patients who satisfied the PART dose constraint had a markedly lower incidence of hs-cTnT elevation (9.7%) compared with those who exceeded the PART dose constraint (46.2%, P = .012). CONCLUSIONS: Clinical implementation of PART model to guide treatment decision within a prospective trial is feasible. The recommended MHD constraints generated by the first version of PART appear reasonable and clinically relevant. PART was associated with lower incidence of hs-cTnT elevation.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lin R, Chen M, Zhang X, et al. Bayesian Learning to Reduce Cardiac Risk of Patients With Locally Advanced Non-Small Cell Lung Cancer Based on Personalized Radiation Therapy Prescription. Int J Radiat Oncol Biol Phys. 2025. PMID: 41365476. doi:10.1016/j.ijrobp.2025.11.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。